Public Sector Pension Investment Board Grows Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Public Sector Pension Investment Board raised its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 23.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 580,967 shares of the company’s stock after buying an additional 110,300 shares during the quarter. Public Sector Pension Investment Board owned about 0.05% of Teva Pharmaceutical Industries worth $10,469,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in TEVA. UMB Bank n.a. grew its holdings in Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after buying an additional 2,067 shares in the last quarter. Beach Investment Counsel Inc. PA purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at approximately $48,000. Smithfield Trust Co lifted its stake in shares of Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares during the last quarter. Byrne Asset Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $52,000. Finally, Claro Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $52,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.55% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Stock Down 0.1 %

Shares of TEVA stock opened at $16.57 on Friday. Teva Pharmaceutical Industries Limited has a 1-year low of $9.35 and a 1-year high of $19.31. The stock’s fifty day moving average price is $17.57 and its 200 day moving average price is $17.35. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89.

Analyst Ratings Changes

Several research firms have recently issued reports on TEVA. UBS Group raised their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Finally, Barclays raised their price target on Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.